

**Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab)
Recombinant Antibody
Catalog # APR10091**

Specification

Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) - Product Information

Application	FC, E, FTA
Primary Accession	P28908
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.48 KDa

Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) - Additional Information

Target/Specificity
TNFRSF8 / CD30

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) - Protein Information

Name TNFRSF8 ([HGNC:11923](#))

Function
Receptor for TNFSF8/CD30L (PubMed:8391931). May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa- B (PubMed:8999898).

Cellular Location
[Isoform 1]: Cell membrane; Single-pass type I membrane protein

Tissue Location


[Isoform 2]: Detected in alveolar macrophages (at protein level).

Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) - Images



Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) is more than 98.99%, determined by SEC-HPLC.



Immobilized human CD30 His at 2 µg/mL can bind Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) □EC₅₀=0.006007 µg/mL